Work

Interferon Lambda: A New Sword in Cancer Immunotherapy

Year: 2011

Type: review

Abstract: The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we and other groups have shown in several animal models a potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy.

Source: Clinical and Developmental Immunology

DOI: 10.1155/2011/349575

Authors: Ahmed Lasfar, Walid Abushahba, Murugabaskar Balan, Karine A. Cohen-Solal

Institutions: Rutgers New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Rutgers Cancer Institute

Language: English

Topic: interferon and immune responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,100